Oncoinvent ASA · OSL:ONCIN
Oncoinvent ASA — ABG Norwegian Biotech Oncology Seminar 2019
14 slides from Oncoinvent ASA's conference presentation, Jun 11, 2019
Slide 1: Oncoinvent AS
Oncoinvent AS ABG Norwegian Biotech Oncology Seminar 11. June 2019 Jan A. Alfheim CEO
Slide 2: Oncoinvent AS
Oncoinvent AS • Founded in 2010 • 3rd company started by serial entrepreneurs Dr. Roy H. Larsen and Professor Øyvind S. Bruland • 19 fulltime employees, 3 Industrial PhDs, 2 part-time Dr. Roy H. Larsen, Ph.D. • Own clinical product production facility Betalutin® Radspherin® Professor of clinical onc
Slide 3: Radspherin®
Radspherin® alpha-emitting microparticles for local applications SPECIALLY DESIGNED CaCO3 microparticles • Carriers for the alpha-emitting isotope • Degradable and non-toxic • Regional retention, very little systemic exposure A NEW alpha-emitting radioisotope Ra-224 • High energetic radiation for ef
Slide 4: Peritoneal carcinomatosis
Peritoneal carcinomatosis Estimated Estimated Estimated new cases incidence in prevalence in with peritoneal 2018* 2018* carcinomatosis Ovarian cancer (all 71 471 217 263 50 029 (70%) types in 7 MM) Colorectal cancer (in Malignant ascites is a 791 057 2 740 594 237 317 (30%) 8 MM) serious condition
Slide 5: Radspherin® therapeutic goal
Radspherin® therapeutic goal «Preserve the surgical complete response» 5
Slide 6: Overview of company highlights since last ABG seminar
Overview of company highlights since last ABG seminar • New Radspherin® efficacy data published • Radspherin® research presented at SNMMI and EANM • CTA sent to NOMA for start of phase I clinical trials • Clinical trial expanded to include colorectal cancer patients • Radspherin® selected for 19.6 M
Slide 7: The Oncoinvent production and lab facilities
The Oncoinvent production and lab facilities Oncoinvent production site inspected and authorized for production of clinical grade Radspherin® by Norwegian Medicines Agency 7
Slide 8: Oncoinvent shareholders
Oncoinvent shareholders* Shareholder Shares % Sciencons AS 3,185,000 24.2 % Geveran Trading Co Ltd. 1,098,000 8.3 % Roy H. Larsen 678,000 5.1 % Radiumhospitalets forskningsstiftelse 670,880 5.1 % No significant changes to the company’s Blaahaugen AS 642,500 4.9 % Must Invest AS 517,000 3.9 % shareho
Slide 9: Oncoinvent organisational growth
Oncoinvent organisational growth • Increased capacity in R&D • Increased capacity in production, QC & QA 9
Slide 10: Recent developments
Recent developments • A preclinical study designed to support multiple injection segment of phase I clinical trials generated unanticipated data • The new data indicated that latest clinical formulation of Radspherin® may not be able to provide the desired therapeutic effect in human trials 10
Slide 11: Number of preclinical therapy and biodistribution studies performed from 2015-2018
Number of preclinical therapy and biodistribution studies performed from 2015 - 2018 Type of Study Number of Studies Number of test subjects Therapy / efficacy 18 439 Biodistribution 11 94 The studies demonstrated a successful proof of principle 11
Slide 12: Next steps
Next steps • The Oncoinvent research team is working on re-adjusting the Radspherin formulation to maximize the therapeutic potential of the drug product • The company intends to enter clinical testing later this year once the new formulation has shown to provide the desired therapeutic effect in a
Slide 13: Innovations for better cancer care
Innovations for better cancer care Thank you for your attention
Slide 14: 14
14
Oncoinvent — ABG Norwegian Biotech Oncology Seminar 2019 on 6ix